Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma
NCI Definition: An aggressive, epidermotropic primary cutaneous T-cell lymphoma. It is characterized by the presence of eruptive papules and nodules, or tumors, which may be localized or disseminated. Morphologically, it is composed of small to medium-sized, or medium-sized to large, CD8-positive T-lymphocytes with pleomorphic or blastic nuclei. Epidermotropism is often pronounced. Angiocentricity and angioinvasion may be present. 
There is 1 clinical trial for primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma, of which 1 is open and 0 are completed or closed. Of the trial that contains primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma as an inclusion criterion, 1 is phase 2 (1 open).
Carboplatin, cyclophosphamide, and dexamethasone are the most common interventions in primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.